pomalidomide has been researched along with carfilzomib in 52 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (carfilzomib) | Trials (carfilzomib) | Recent Studies (post-2010) (carfilzomib) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 748 | 121 | 716 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (3.85) | 29.6817 |
| 2010's | 40 (76.92) | 24.3611 |
| 2020's | 10 (19.23) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
| Jagannath, S | 1 |
| Stewart, AK | 2 |
| Schots, R | 1 |
| Hata, H | 1 |
| Niesvizky, R | 1 |
| Arima, N; Kawada, H | 1 |
| Mahindra, A; Saini, N | 1 |
| Ahluwalia, R; Carson, KR; Cox, DP; Fiala, MA; Jaenicke, M; Moliske, CC; Stockerl-Goldstein, KE; Tomasson, MH; Trinkaus, KM; Vij, R; Wang, TF; Wildes, TM | 1 |
| Lokhorst, HM; van de Donk, NW | 1 |
| El-Amm, J; Tabbara, IA | 1 |
| Mateos, MV; Ocio, EM; San Miguel, JF | 1 |
| Orlowski, RZ | 1 |
| Chen, SE; Highsmith, KN; Horowitz, S | 1 |
| Gentili, S; Lonial, S | 1 |
| Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L | 1 |
| Kuroda, J | 1 |
| Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG | 1 |
| Lonial, S; Usmani, SZ | 1 |
| Colson, K | 1 |
| Moreau, P; Touzeau, C | 1 |
| Anderson, KC | 1 |
| Dimopoulos, MA; Palumbo, A; San-Miguel, J; Siegel, D; Sonneveld, P | 1 |
| Boise, LH; Kaufman, J; Lonial, S | 1 |
| Abonour, R; Bensinger, WI; Cohen, AD; Durie, BG; Gasparetto, C; Gomes, CL; Kaufman, JL; Lentzsch, S; Orlowski, RZ; Pascucci, N; Shah, JJ; Smith, DD; Stadtmauer, EA; Vogl, DT | 1 |
| Ito, S | 1 |
| Bolomsky, A; Ludwig, H; Schlangen, K; Schreiner, W; Zojer, N | 1 |
| Rochau, U; Siebert, U; Weger, R; Willenbacher, E; Willenbacher, W | 1 |
| Jung, CK; Jung, Y; Kang, SW; Kim, BG; Kim, TH; Lee, SE; Lim, JY; Min, CK; Park, E; Park, J; Won, KA | 1 |
| Biran, N; Duma, N; Richter, J; Siegel, D; Vesole, DH | 1 |
| Broijl, A; Sonneveld, P | 1 |
| Fan, L; Hu, C; Ma, X; Ran, X; Yu, H; Zou, Y | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kastritis, E; Terpos, E | 1 |
| Abudayyeh, A; Doshi, M; Edeani, A; Glezerman, IG; Jhaveri, KD; Monga, D; Rosner, M; Wanchoo, R | 1 |
| Boccadoro, M; Bonello, F; Larocca, A; Salvini, M | 1 |
| Abouzaid, S; Chen, CC; Hussein, M; McGuiness, CB; Parikh, K; Purnomo, L; Wade, RL | 1 |
| Abouzaid, S; Ailawadhi, S; Chandler, C; Guo, S; Mouro, J; Parikh, K; Pelligra, CG | 1 |
| Costello, C; Mikhael, JR | 1 |
| Sonneveld, P | 1 |
| Belotti, A; Bertazzoni, P; Boccadoro, M; Bringhen, S; Cafro, AM; De Paoli, L; Fanin, R; Gaidano, G; Liberati, AM; Lombardo, A; Mina, R; Palumbo, A; Patriarca, F; Rossi, G; Sonneveld, P; Spada, S; Troia, R | 1 |
| Borsi, E; Cavo, M; Mancuso, K; Martello, M; Pantani, L; Rocchi, S; Santacroce, B; Tacchetti, P; Terragna, C; Zamagni, E | 1 |
| Tomlinson, R | 1 |
| Chung, DJ; Diamond, B; Lesokhin, AM; Maclachlan, K; Ola Landgren, C | 1 |
| Berenson, JR; Eades, B; Emamy-Sadr, M; Regidor, B; Spektor, TM; Swift, R; Tarhini, F | 1 |
| Andriani, A; Annibali, O; Antolino, G; Cantonetti, M; Cimino, G; Coppetelli, U; De Rosa, L; De Stefano, V; di Toritto, TC; La Verde, G; Petrucci, MT; Piciocchi, A; Rizzo, M; Siniscalchi, A; Vozella, F; Za, T | 1 |
| Asset, G; Baker, R; Capra, M; Dimopoulos, MA; Facon, T; Hajek, R; Kim, K; Koh, Y; Leleu, X; Macé, S; Martin, T; Martinez, G; Mikhael, J; Min, CK; Moreau, P; Oriol, A; Pour, L; Risse, ML; Špička, I; Suzuki, K; Yong, K | 1 |
| Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 1 |
| Berenson, JR; Eades, B; Eshaghian, S; Ghermezi, M; Lim, S; Martinez, D; Schwartz, G; Spektor, TM; Swift, RA; Vescio, R; Yashar, D | 1 |
| Aslam, M; Gul, E; Jimenez-Zepeda, VH; Kardjadj, M; Kotb, R; LeBlanc, R; Louzada, M; Masih-Khan, E; McCurdy, A; Mian, H; Reece, D; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D | 1 |
| Berdeja, J; Cole, C; Derman, BA; Griffith, K; Jakubowiak, AJ; Jasielec, J; Kin, A; Major, A; Reece, D; Stefka, AT; Zonder, J | 1 |
| Buadi, F; Dingli, D; Dispenzieri, A; Fonder, A; Gertz, MA; Go, R; Gonsalves, W; Hayman, S; Hobbs, M; Hwa, Y; Kapoor, P; Kourelis, T; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Muchtar, E; Rajkumar, SV; Siddiqui, M; Vaxman, I; Warsame, R | 1 |
25 review(s) available for pomalidomide and carfilzomib
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |
Novel therapies for relapsed myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drugs, Investigational; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mice; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Salvage Therapy; Thalidomide | 2009 |
[Development of novel agents for multiple myeloma; now and the future].
Topics: Animals; Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Benzoquinones; Benzylamines; Clinical Trials as Topic; Cyclams; Drug Discovery; Drug Therapy, Combination; Heterocyclic Compounds; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Molecular Targeted Therapy; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Thalidomide; Vorinostat | 2011 |
Novel therapies in monoclonal gammopathies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide | 2012 |
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Plasmacytoma; Pyrazines; Thalidomide | 2012 |
Therapeutic strategies for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Immune System; Immunotherapy; Lenalidomide; Multiple Myeloma; Oligopeptides; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Thalidomide | 2013 |
Emerging therapies in multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Signal Transduction; Thalidomide | 2015 |
Novel generation of agents with proven clinical activity in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrroles; Recurrence; Thalidomide; Treatment Outcome | 2013 |
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat | 2013 |
Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Survival Rate; Thalidomide; Treatment Outcome | 2014 |
Relapsed and refractory multiple myeloma: new therapeutic strategies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Remission Induction; Thalidomide; Treatment Outcome | 2014 |
Pomalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Thalidomide | 2014 |
[Current status of clinical trials of novel agents for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Approval; Drug Discovery; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lactones; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Pyrroles; Thalidomide; Vorinostat | 2014 |
Current treatment landscape for relapsed and/or refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
Novel drug combinations for the management of relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease Management; Disease Progression; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Recurrence; Thalidomide | 2014 |
Treatment-related symptom management in patients with multiple myeloma: a review.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Quality of Life; Thalidomide | 2015 |
Multiple myeloma: from front-line to relapsed therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Humans; Methotrexate; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Randomized Controlled Trials as Topic; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Vincristine | 2015 |
Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Risk Factors; Thalidomide | 2015 |
Treatment of relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Palliative Care; Plasma Cells; Precision Medicine; Proteasome Inhibitors; Recurrence; Thalidomide | 2016 |
Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Management; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Prospective Studies; Salvage Therapy; Thalidomide | 2017 |
Current treatments for renal failure due to multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Renal Insufficiency; Thalidomide | 2016 |
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Everolimus; Humans; Imidazoles; Immunologic Factors; Indoles; Kidney Diseases; Lenalidomide; Multiple Myeloma; Nivolumab; Oligopeptides; Oximes; Proteasome Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Thalidomide; Vemurafenib | 2017 |
Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Topics: Antineoplastic Agents; Boron Compounds; Dose-Response Relationship, Drug; Glycine; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Survival Rate; Thalidomide | 2017 |
Management of multiple myeloma in the relapsed/refractory patient.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Recurrence; Thalidomide | 2017 |
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Topics: Adaptive Clinical Trials as Topic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Thalidomide; Transplantation, Autologous; Withholding Treatment | 2020 |
5 trial(s) available for pomalidomide and carfilzomib
| Article | Year |
|---|---|
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Oligopeptides; Pneumonia; Pulmonary Embolism; Recurrence; Thalidomide; Time Factors | 2015 |
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Dexamethasone; Follow-Up Studies; Humans; Multiple Myeloma; Oligopeptides; Prognosis; Survival Rate; Thalidomide | 2018 |
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Dexamethasone; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Progression-Free Survival; Prospective Studies; Recurrence; Thalidomide | 2021 |
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide | 2022 |
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma | 2023 |
22 other study(ies) available for pomalidomide and carfilzomib
| Article | Year |
|---|---|
New drugs in multiple myeloma and the significance of autologous stem cell transplants.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Stem Cell Transplantation; Thalidomide | 2009 |
Recent advances in myeloma treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide | 2011 |
Novel therapeutics in multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide; Vorinostat | 2012 |
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Lenalidomide; Logistic Models; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Oligopeptides; Outcome Assessment, Health Care; Prognosis; Pyrazines; Retrospective Studies; Risk Factors; Survival Analysis; Thalidomide | 2014 |
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Recurrence; Thalidomide | 2013 |
Multiple myeloma: new uses for available agents, excitement for the future.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Proteasome Inhibitors; Thalidomide | 2015 |
How I treat high-risk myeloma.
Topics: Aged; Antineoplastic Agents; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide | 2015 |
[Novel agents in multiple myeloma treatment].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Multiple Myeloma; Oligopeptides; Protein Kinase Inhibitors; Signal Transduction; Thalidomide | 2015 |
Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Dexamethasone; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 2-Ring; Human Umbilical Vein Endothelial Cells; Humans; Multiple Myeloma; Neovascularization, Physiologic; Oligopeptides; Osteogenesis; Polycomb Repressive Complex 1; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Thiazoles; Tumor Microenvironment | 2016 |
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Prognosis; Recurrence; Registries; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2016 |
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Boron Compounds; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Glycine; Humans; Male; Mice; Middle Aged; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Thalidomide; Xenograft Model Antitumor Assays | 2016 |
Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Kidney Diseases; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide | 2017 |
Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Retrospective Studies; Thalidomide | 2017 |
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Disease-Free Survival; Drug Costs; Drug Resistance, Neoplasm; Humans; Models, Economic; Multiple Myeloma; Oligopeptides; Quality-Adjusted Life Years; Recurrence; Thalidomide; United States | 2017 |
Therapy sequencing strategies in multiple myeloma: who, what and why?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Glycine; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Thalidomide | 2018 |
Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Thalidomide | 2018 |
Multiple myeloma: Updated approach to management in 2018.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Bortezomib; Disease Management; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Pain; Prognosis; Renal Insufficiency; Serum Albumin; Thalidomide | 2018 |
Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hypophosphatemia; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Retrospective Studies; Thalidomide | 2021 |
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Oligopeptides; Progression-Free Survival; Thalidomide | 2021 |
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Canada; Dexamethasone; Female; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2021 |
Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Thalidomide | 2022 |
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Multiple Myeloma; POEMS Syndrome; Thalidomide | 2023 |